Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda And Enterome To Jointly Mine The Microbiome

This article was originally published in PharmAsia News

Executive Summary

In a deal that further expands its credentials, French company Enterome has inked an alliance with Japan's Takeda to conduct research and develop novel therapeutics aimed at microbiome targets thought to play crucial roles in gastrointestinal disorders.

You may also be interested in...

EU Supports Microbiome R&D Via Enterome

France's leading microbiome company, Enterome, has raised €32m in a series D financing and secured a €40m loan facility from the European Investment Bank to advance a small molecule and a potential cancer vaccine approach into early-stage clinical studies.

Deals Of The Year: Cast Your Vote For Top Alliance Of 2017

It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.

Enterome Building A Microbiome R&D Presence Via Pharma Deals

The number of microbiome-based companies is growing with scientific breakthroughs in this area. Pierre Belichard, CEO of the French gut microbiome focused company Enterome, talked to Scrip at the Biotrinity 2017 meeting in London about its partnerships, pipeline progress and his plans for the future.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts